London Stock Exchange ShareChat and ADVFN, analyst sentiment sits at a Strong Buy:22 May 2026 14:24
Broad Market Consensus
According to tracking data across aggregate platforms like London Stock Exchange ShareChat and ADVFN, analyst sentiment sits at a Strong Buy:
Conservative Average Target: 4.0p to 7.0p.
High-End Speculative Estimates: Up to 30.0p.
Valuation Forecast: Independent estimates (such as Trinity Delta) model the fundamental underlying value of the technology portfolio at up to £118 million, or roughly 37p per share, once wider commercial adoption by pharmaceutical groups is achieved.
CelLBxHealth plc (formerly known as ANGLE plc) is a global precision circulating tumour cell (CTC) intelligence company that has pivoted to a partner-led commercial strategy. The company uses its proprietary Parsortix platform to isolate intact cancer cells from blood draws.
To accelerate the adoption of liquid biopsy in clinical oncology, drug development, and precision medicine, CelLBxHealth has established several key global partnerships:
Clinical & Healthcare Providers
AdventHealth: A major clinical collaboration utilizing CTC-based monitoring across two extensive cancer studies. This partnership aims to track how tumours evolve during treatment using simple blood draws, moving advanced oncology monitoring closer to patients' homes across AdventHealth's extensive US network.
The Royal Marsden NHS Foundation Trust: Ongoing research collaborations in the UK to generate strong clinical data validating CTC-based liquid biopsies, including specific studies on lung cancer.
Molecular Diagnostic Industry Giants
CelLBxHealth collaborates with prominent multinational diagnostic corporations to validate workflows that merge CTC technology with existing tissue and circulating tumour DNA (ctDNA) tests:
QIAGEN: A non-exclusive Collaboration and Co-Marketing Agreement to offer the Parsortix platform alongside QIAGEN’s molecular technologies (PCR, NGS) to pharma partners.
Roche Diagnostics: Partnership aimed at workflow validation and leveraging their massive installed platform base.
Illumina: Collaborative workflows to integrate cell harvesting with full genomic next-generation sequencing (NGS).
Myriad Genetics: Collaborations targeted at incorporating CTC workflows alongside downstream genetic profiling.
Biotech & Technology Developers
BioView Ltd: A strategic partnership dedicated to developing an automated human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer tracking.
NuProbe USA, Inc.: An agreement allowing CelLBxHealth to utilize a pan-cancer next-generation sequencing panel for downstream profiling of captured cells.
Global Biopharma Companies: Commercial partnerships with top-tier pharmaceutical groups and specialist Contract Research Organisations (CROs) to integrate CTC analysis into active drug development pipelines.
Sign In
Follow the stocks
